Literature DB >> 27042844

Long-term follow-up of (90)Y-ibritumomab-tiuxetan ((90)YIT) in the conditioning of autologous hematopoietic transplantation for indolent and mantle cell lymphomas in a single French center.

L Philippe1, P Helias2, M Puyraveau3, H Boulahdour4, E Deconinck1, E Daguindau1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27042844     DOI： 10.1038/bmt.2016.67

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  13 in total

1.  Effect of cell determinant (CD)34+ cell dose on the cost and consequences of peripheral blood stem cell transplantation for non-Hodgkin's lymphoma patients in front-line therapy.

Authors:  S Limat; M C Woronoff-Lemsi; N Milpied; I Chartrin; N Ifrah; E Deconinck; R Gressin; P Colombat; J Y Cahn; P Arveux
Journal:  Eur J Cancer       Date:  2000-12       Impact factor: 9.162

2.  Improving survival in patients with transformed B cell non Hodgkin lymphoma: consolidation with ⁹⁰Yttrium ibritumomab tiuxetan-BEAM and autologous stem cell transplantation.

Authors:  Marielle J Wondergem; Josee M Zijlstra; Madelon de Rooij; Otto J Visser; Peter C Huijgens; Sonja Zweegman
Journal:  Br J Haematol       Date:  2012-01-09       Impact factor: 6.998

3.  A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma.

Authors:  Auayporn Nademanee; Stephen Forman; Arturo Molina; Henry Fung; David Smith; Andy Dagis; Cheuk Kwok; Dave Yamauchi; Anne-Line Anderson; Peter Falk; Amrita Krishnan; Mark Kirschbaum; Neil Kogut; Ryotaro Nakamura; Margaret O'donnell; Pablo Parker; Leslie Popplewell; Vinod Pullarkat; Roberto Rodriguez; Firoozeh Sahebi; Eileen Smith; David Snyder; Anthony Stein; Ricardo Spielberger; Jasmine Zain; Christine White; Andrew Raubitschek
Journal:  Blood       Date:  2005-07-07       Impact factor: 22.113

4.  Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma.

Authors:  Avichai Shimoni; S Tzila Zwas; Yakov Oksman; Izhar Hardan; Noga Shem-Tov; Ronit Yerushalmi; Abraham Avigdor; Isaac Ben-Bassat; Arnon Nagler
Journal:  Exp Hematol       Date:  2007-04       Impact factor: 3.084

5.  rHuEpo before high-dose therapy allows autologous peripheral stem-cell transplantation without red blood cell transfusion: a pilot study.

Authors:  M Hunault-Berger; A Tanguy-Schmidt; P Rachieru; V Lévy; M Truchan-Graczyk; S Francois; M Gardembas-Pain; M Dib; C Foussard; N Piard; A Godon; P Solal-Celigny; N Ifrah
Journal:  Bone Marrow Transplant       Date:  2005-05       Impact factor: 5.483

6.  A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma.

Authors:  Avichai Shimoni; Irit Avivi; Jacob M Rowe; Moshe Yeshurun; Itai Levi; Reuven Or; Paulina Patachenko; Abraham Avigdor; Tzila Zwas; Arnon Nagler
Journal:  Cancer       Date:  2012-01-17       Impact factor: 6.860

7.  Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma.

Authors:  Stephen M Ansell; Kay M Ristow; Thomas M Habermann; Gregory A Wiseman; Thomas E Witzig
Journal:  J Clin Oncol       Date:  2002-09-15       Impact factor: 44.544

8.  Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma.

Authors:  Amrita Krishnan; Auayporn Nademanee; Henry C Fung; Andrew A Raubitschek; Arturo Molina; Dave Yamauchi; Roberto Rodriguez; Ricardo T Spielberger; Peter Falk; Joycelynne M Palmer; Stephen J Forman
Journal:  J Clin Oncol       Date:  2007-11-19       Impact factor: 44.544

9.  Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy.

Authors:  Myron S Czuczman; Christos Emmanouilides; Mohamed Darif; Thomas E Witzig; Leo I Gordon; Stephen Revell; Katie Vo; Arturo Molina
Journal:  J Clin Oncol       Date:  2007-08-20       Impact factor: 44.544

10.  Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma.

Authors:  Jane N Winter; David J Inwards; Stewart Spies; Gregory Wiseman; David Patton; William Erwin; Alfred W Rademaker; Bing Bing Weitner; Stephanie F Williams; Martin S Tallman; Ivana Micallef; Jayesh Mehta; Seema Singhal; Andrew M Evens; Michael Zimmer; Arturo Molina; Christine A White; Leo I Gordon
Journal:  J Clin Oncol       Date:  2009-03-02       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.